Scarica l'app Stockscreener
0.8322
5.82%
0.0458
Icecure Medical Ltd Borsa (ICCM) Ultime notizie
IceCure Medical Ltd (NASDAQ:ICCM) Q3 2024 Earnings Call Transcript - Insider Monkey
IceCure Medical’s sales grow 36% in nine months of 2024 - Medical Buyer
IceCure Receives Notice of Allowance from U.S. Patent and Tradem - GuruFocus.com
IceCure Medical Sees Strong Growth Amid ProSense® Adoption - TipRanks
IceCure Medical Ltd Reports Earnings Results for the Nine Months Ended September 30, 2024 - Marketscreener.com
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - PR Newswire
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office - Yahoo Canada Finance
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 - PR Newswire
IceCure gets favorable FDA AdCom vote for ProSense System - MSN
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Au - GuruFocus.com
IceCure Medical Sets Q3 2024 Earnings Call Date; Cryoablation Developer to Update Investors | ICCM Stock News - StockTitan
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health - Marketscreener.com
IceCure's ProSense® Selected for Major European Breast Cancer Treatment Study | ICCM Stock News - StockTitan
Market Sentiment Around Loss-Making IceCure Medical Ltd (NASDAQ:ICCM) - Simply Wall St
Icecure wins advisory nod for Prosense system for breast cancer - BioWorld Online
IceCure’s cryoablation system for breast cancer treatment gains FDA panel support - Yahoo Finance
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer - The Malaysian Reserve
ICCMIceCure Medical Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Icecure Medical Ltd (ICCM) Is A Good Stock To Invest In - Stocks Register
IceCure's ProSense Cancer Treatment Wins Crucial FDA Panel Vote, Shares Surge | ICCM Stock News - StockTitan
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoabl - GuruFocus.com
IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023 - BioSpace
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - Marketscreener.com
Independent Study Results in Japan Demonstrate Zero (0%) Breast - GuruFocus.com
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 - GuruFocus.com
Globus Medical (NYSE:GMED) & IceCure Medical (NASDAQ:ICCM) Head-To-Head Contrast - Defense World
IceCure receives US patent allowance for cryoablation system - Investing.com
IceCure receives US patent allowance for cryoablation system By Investing.com - Investing.com Australia
IceCure Announces FDA Advisory Panel Meeting Date for Marketing - GuruFocus.com
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System - Marketscreener.com
Indo-Asian News Service - IANS India Pvt Ltd
Analytical Overview: Icecure Medical Ltd (ICCM)’s Ratios Tell a Financial Story - The Dwinnex
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablati - GuruFocus.com
Best Penny Stocks Under $1 To Buy Now - AOL
Icecure Medical Ltd (ICCM) shows promising results - US Post News
Ratios in Focus: Analyzing Icecure Medical Ltd (ICCM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
ICCM stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com UK
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference - StreetInsider.com
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Yahoo Finance
IceCure reports high success rate in breast cancer trial By Investing.com - Investing.com Australia
Ex-ad industry employees launch a new digital agency 'itch' - afaqs!
IceCure reports high success rate in breast cancer trial - Investing.com India
Why Is Interactive Strength Stock Surging Today? - Benzinga
InCred's Aditya Sood Reveals Key Factors Behind Selecting Indraprastha Medical From Hospital Sector - Business Today
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96 - StreetInsider.com
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate - PR Newswire
The time has not yet come to remove your chips from the table: Icecure Medical Ltd (ICCM) - SETE News
What will the future hold for Icecure Medical Ltd (NASDAQ:ICCM) stock? - US Post News
FDA AdComm to discuss IceCure's ProSense on Nov. 7 - MSN
Study: Liquid Nitrogen-Based Cryoablation Safe for Treating Treating Tumors of the Lung, Bone and Soft Tissues - Imaging Technology News
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues - StockTitan
H.C. Wainwright maintains Buy rating on IceCure Medical stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy rating on IceCure Medical stock - Investing.com India
Icecure Medical Ltd (ICCM) deserves closer scrutiny - US Post News
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):